Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of serious bacterial infections and rare diseases, with an emphasis on addressing areas of high unmet medical need. The company operates primarily within the biotechnology and pharmaceuticals industry, particularly in the anti-infectives and rare disease segments. Its business model centers on advancing internally developed drug candidates through clinical development and leveraging partnerships or asset transactions to generate capital.
Historically, Spero’s core focus has been on developing treatments for drug-resistant bacterial infections, positioning the company within a strategically important but commercially challenging segment of the pharmaceutical market. The company was founded in 2013 and went public in 2017, using proceeds to advance its antibiotic pipeline. Over time, Spero has restructured its portfolio to prioritize programs with differentiated mechanisms and clearer regulatory and commercial pathways, reflecting evolving market dynamics and capital constraints in antibiotic development.
Business Operations
Spero Therapeutics’ operations are organized around the research and development of proprietary therapeutic candidates rather than commercialized products. Its pipeline has included both antibacterial agents and rare disease therapies, with revenue historically derived from collaboration agreements, licensing transactions, and asset sales, rather than product sales. The company does not currently maintain large-scale manufacturing or commercial infrastructure, relying instead on third-party contractors for clinical development and manufacturing activities.
The company’s activities are primarily based in the United States, with clinical trials and research collaborations extending internationally as required. Spero has entered into strategic partnerships with larger pharmaceutical companies for development or monetization of specific assets. Some historical transactions and partnership outcomes have been disclosed in public filings, but certain program-level financial details vary across disclosures; where discrepancies exist, data inconclusive based on available public sources.
Strategic Position & Investments
Strategically, Spero Therapeutics has focused on capital efficiency and portfolio prioritization, concentrating resources on programs with the strongest clinical and regulatory rationale. Growth initiatives have included advancing lead candidates into mid-stage clinical trials and monetizing non-core assets to extend the company’s operating runway. This strategy reflects broader industry challenges in antibiotic development, where reimbursement and commercialization risks remain significant.
The company has made selective investments in its pipeline rather than maintaining a broad portfolio. Certain assets have been partnered with or transferred to larger pharmaceutical companies, allowing Spero to retain potential downstream value while reducing development risk. The precise long-term strategic balance between internal development and external partnerships continues to evolve, and some future plans remain subject to change based on financing and clinical outcomes, as indicated in public disclosures.
Geographic Footprint
Spero Therapeutics is headquartered in Cambridge, Massachusetts, a major hub for biotechnology research and development in the United States. Its primary operational footprint is domestic, encompassing corporate management, research oversight, and clinical program coordination.
Internationally, the company’s presence is indirect, primarily through global clinical trial sites, contract research organizations, and past or present partnerships with multinational pharmaceutical companies. While Spero does not operate foreign subsidiaries with large standalone operations, its development programs have involved patients, investigators, and regulatory interactions across North America, Europe, and other regions as required for clinical development.
Leadership & Governance
Spero Therapeutics was co-founded by experienced biotechnology entrepreneurs and has been led by executives with backgrounds in drug development, infectious disease, and capital markets. The leadership team emphasizes scientific rigor, disciplined capital allocation, and strategic partnering as core elements of its operating philosophy.
Key members of the executive leadership team include:
- Ankit Mahadevia, M.D. – President and Chief Executive Officer
- Javier San Martin, M.D. – Chief Medical Officer
- Paul D. Eisenberg – Chief Financial Officer
- Michael W. Callahan, M.D. – Senior Vice President, Drug Development
The board of directors provides oversight with experience spanning biotechnology, pharmaceuticals, and corporate governance, supporting management’s focus on long-term value creation and responsible development practices.